NewBiologix and Synastra Join Forces to Advance rAAV Manufacturing for Duchenne Gene Therapy
The collaboration brings together Synastra’s expertise in genomic engineering, AAV vector design, rare-disease gene therapy, and translational development with NewBiologix’s proprietary cell engineering and rAAV manufacturing technologies. The post NewBiologix and Synastra Join Forces to Advance rAAV Manufacturing for Duchenne Gene Therapy appeared first on GEN - Genetic Engineering and…
NewBiologix and Synastra have entered into an agreement to collaborate on advancing the manufacturing of an investigational Duchenne muscular dystrophy (DMD) gene therapy using the rAAV (recombinant adeno-associated virus) platform. NewBiologix, a Switzerland-based company, will use its Xcell stable manufacturing platform to generate and characterize a research cell bank for Synastra's DMD gene therapy candidate.
The collaboration aims to establish a genetically defined, reproducible, and scalable production system that can support the program's progression towards clinical translation and, ultimately, commercial supply. This partnership brings together Synastra's expertise in genomic engineering, AAV vector design, rare-disease gene therapy, and translational development with NewBiologix's proprietary cell engineering and rAAV manufacturing technologies.
Brief written by urgent.news from GEN Biotechnology's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
